Mediclinic’s underwhelming half-year results have raised questions about Remgro’s holding in the group It might be worth getting a second opinion of stalwart investment company Remgro after the market cast a jaundiced eye across the interim numbers posted by Mediclinic International, its 44.6%-held private hospitals subsidiary.Since the initial euphoria died down around Mediclinic securing a primary listing on the London Stock Exchange (LSE) — via a reverse takeover of hospital group Al Noor — sentiment for the shares of the enlarged private hospitals conglomerate has looked vulnerable. In three months Mediclinic lost more than 30% of its market value on the JSE. After the release of interim results last week, the share dropped almost 10% in one day.Understandably, Remgro’s shares on the JSE have been dragged down by developments at Mediclinic. In the end-June financial results Mediclinic accounted for a chunky 44% of Remgro’s intrinsic value of R158bn.While existing Remgro shareho...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now